List of Viltepso drug patents
Viltepso is owned by Nippon Shinyaku.
Viltepso contains Viltolarsen.
Viltepso has a total of 2 drug patents out of which 0 drug patents have expired.
Viltepso was authorised for market use on 12 August, 2020.
Viltepso is available in solution;intravenous dosage forms.
Viltepso can be used as treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping.
Drug patent challenges can be filed against Viltepso from August, 2024.
The generics of Viltepso are possible to be released after 31 August, 2031.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10870676 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(8 years from now) | |
| US9079934 | NIPPON SHINYAKU | Antisense nucleic acids |
Aug, 2031
(8 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 12, 2025 |
| Orphan Drug Exclusivity (ODE) | Aug 12, 2027 |
Drugs and Companies using VILTOLARSEN ingredient
NCE-1 date: August, 2024
Market Authorisation Date: 12 August, 2020
Treatment: Treatment of duchenne muscular dystrophy (dmd) in patients who have a confirmed mutation of the dmd gene that is amenable to exon 53 skipping
Dosage: SOLUTION;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic